

**Table 4 - PKC and PI3-K regulation of *I<sub>sc</sub>*.** Effects of PKC activator and PI3-K inhibitors on *I<sub>sc</sub>* and *R<sub>T</sub>*.

| Condition                         | (n) | Amiloride-sensitive <i>I<sub>sc</sub></i> (μA/cm <sup>2</sup> ) | <i>R<sub>T</sub></i> (Kohm-cm <sup>2</sup> ) |
|-----------------------------------|-----|-----------------------------------------------------------------|----------------------------------------------|
| DEX                               | (3) | 11.9 ± 0.9                                                      | 2.37 ± 0.13                                  |
| DEX + PMA (100 nM; 24 hr)         | (3) | 6.0 ± 0.6*                                                      | 3.04 ± 0.15*                                 |
| DEX                               | (3) | 11.6 ± 0.3                                                      | 2.81 ± 0.26                                  |
| DEX + 4-alpha-PDD (100 nM; 24 hr) | (3) | 11.3 ± 0.5                                                      | 3.01 ± 0.21                                  |
| DEX                               | (3) | 10.4 ± 0.7                                                      | 1.48 ± 0.35                                  |
| DEX + LY 294002 (20 μM; 9 hr)     | (3) | 4.0 ± 0.6*                                                      | 4.13 ± 0.02*                                 |
| DEX                               | (3) | 11.6 ± 0.7                                                      | 2.42 ± 0.17                                  |
| DEX + LY 303115 (20 μM; 9 hr)     | (3) | 10.5 ± 0.4                                                      | 2.60 ± 0.20                                  |
| DEX                               | (3) | 11.6 ± 0.3                                                      | 2.81 ± 0.26                                  |
| DEX + Wortmannin (100 nM; 9 hr)   | (3) | 9.6 ± 0.3*                                                      | 2.35 ± 0.33                                  |

Response of amiloride (10 μM)-sensitive *I<sub>sc</sub>* and transepithelial resistance (*R<sub>T</sub>*) by SCCD epithelia to dexamethasone (DEX [100 nM; 24 hr]) treatment in the presence and absence of either PKC activator or PI3-K inhibitors. Each pair of control and treated epithelia cultures were taken from one batch of SCCD monolayers. *R<sub>T</sub>*, transepithelial resistance. Values are means ± SEM; n, number of experiments in parenthesis. DEX, dexamethasone; PMA, Phorbol-12-myristate-13-acetate; 4-alpha-PDD, 4-alpha-phorbol-12, 13-didecanoate; LY 294002, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; LY 303511, 2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one. The unpaired *t*-test was used to compare DEX to DEX + PKC activator and DEX + PI3-K inhibitors. \**P* < 0.05. SCCD, semicircular canal duct epithelium.